Evidence map›Paper›PMID 22677312›Full record

ArticleBioorganic & medicinal chemistry letters2012

Haloenol pyranones and morpholinones as antineoplastic agents of prostate cancer.

Jason N Mock, John P Taliaferro, Xiao Lu, Sravan Kumar Patel, Brian S Cummings, Timothy E Long

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jason N MockDepartment of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602-2352, USA.
John P Taliaferro
Xiao Lu
Sravan Kumar Patel
Brian S Cummings
Timothy E Long

Funding

sPLA2 Selective Degradation of NanoparticlesR21EB008153 · NIBIB · UNIVERSITY OF GEORGIA · PI ARNOLD, ROBERT D, CUMMINGS, BRIAN S · 2009 to 2010
$408k
NIBIB NIH HHS EB08153NIBIB NIH HHS R21 EB008153
6 · The paper itself

Abstract

Haloenol pyran-2-ones and morpholin-2-ones were synthesized and evaluated as inhibitors of cell growth in two different prostate human cancer cell lines (PC-3 and LNCaP). Analogs derived from L- and D-phenylglycine were found to be the most effective antagonists of LNCaP and PC-3 cell growth. Additional studies reveal that the inhibitors induced G2/M arrest and the (S)-enantiomer of the phenylglycine-based derivatives was a more potent inhibitor of cytosolic iPLA(2)β.

Indexed as

AnimalsAntineoplastic AgentsCell Line, TumorCell SurvivalHumansMaleMolecular StructureMorpholinesProstatic NeoplasmsPyransRatsStructure-Activity RelationshipAntineoplastic AgentsmorpholineMorpholinesPyrans

Identifiers

PMID22677312
PMCPMC3376906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.